Skip to main
  1. Stocks
  2. Entera Bio Ltd
  3. Forecast
ENTX

ENTX Stock Forecast & Price Target

ENTX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Entera Bio is positioned as an attractive oral-peptide platform story because its N-Tab technology tackles a major formulation barrier—protecting peptides in the GI tract while enabling absorption—creating multiple shots on goal beyond the lead asset. EB613 has the strongest fundamentals: it mirrors Forteo’s active ingredient, has shown Phase 2 efficacy and a safety profile broadly similar to Forteo, and benefits from FDA alignment on a single 12-month Phase 3 with a BMD endpoint, which meaningfully de-risks development and could support a faster path to market. The company also has meaningful financial and strategic optionality, with a fully diluted market cap of just ~$565M and ~$255M in pro-forma cash after a July PIPE, while EB613, EB612, EB618, and GLP-2 each address large underserved markets.

Bears say

Entera Bio is burdened by a highly uncertain, single-lead outlook because EB613 is still in clinical development and must clear a 12-month Phase 3 hurdle in a crowded osteoporosis market against entrenched injectables and generics, with risks that PK variability, underwhelming BMD gains, or FDA limitations on labeling could blunt adoption. Financially, the company had just $11.3M in cash and cash equivalents at the end of 2Q 2026 before a $275M private placement in July 2026, but management still expects operations to run into 2030 while profitability is not expected until 2032, implying continued funding risk and future dilution. The bearish view is reinforced by reimbursement and pricing pressure, since payers may resist covering EB613 at a premium to Forteo and could favor lower-cost, established therapies even if the oral format is more convenient.

ENTX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Entera Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

ENTX Analyst Forecast & Price Prediction

Get the latest ENTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ENTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Entera Bio Ltd (ENTX) Forecast

Analysts have given ENTX a Buy based on their latest research and market trends.

According to 4 analysts, ENTX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Entera Bio Ltd (ENTX)


ENTX Analyst Forecast & Price Prediction

Get the latest ENTX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ENTX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ENTX stock data and trends